---
title: 'Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered
  CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies
  (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study'
date: '2024-12-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39617017/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20241202180329&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'BACKGROUND: Effective treatment options are scarce for relapsed or refractory
  T-cell lymphoma. This study assesses the safety and activity of CTX130 (volamcabtagene
  durzigedleucel), a CD70-directed, allogeneic chimeric antigen receptor (CAR) immunotherapy
  manufactured from healthy donor T cells, in patients with relapsed or refractory
  T-cell ...'
disable_comments: true
---
BACKGROUND: Effective treatment options are scarce for relapsed or refractory T-cell lymphoma. This study assesses the safety and activity of CTX130 (volamcabtagene durzigedleucel), a CD70-directed, allogeneic chimeric antigen receptor (CAR) immunotherapy manufactured from healthy donor T cells, in patients with relapsed or refractory T-cell ...